Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 224

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 224
---
 follows:

| ​                                 | ​ | ​                |       ​ |
| Lease Liability Maturity Analysis |   | Operating Leases |         |
| 2024                              |   | ​                | 155,242 |
| 2025                              | ​ | ​                |  81,107 |
| 2026                              | ​ | ​                |  82,325 |
| Total lease payments              |   | ​                | 318,674 |
| Less: Imputed Interest            |   | ​                | -55,997 |
| Total                             | ​ | $                | 262,677 |

Future minimum sublease income under non-cancelable leases as of December 31, 2023, were as follows:

| ​               
 Sublease income | ​ | ​                
 Operating Leases |      ​ |
|:----------------|:--|:-----------------|-------:|
| 2024            | ​ | $                | 56,000 |
| ​               | ​ | ​                |      ​ |
| Total           | ​ | $                | 56,000 |

As of December 31, 2023, and 2022, the Company had no operating leases that had not yet commenced.

F-19

#### 10)     Stockholders’ Equity
On December 21, 2023, the Company approved a one-time grant under the Company’s Amended and Restated 2020 Omnibus Incentive Compensation Plan (the “Plan”) to Fady Boctor, the Company’s President and Chief Commercial Officer, of 49,645 shares of the Company’s common stock.

Also on December 21, 2023, the Company approved and accrued for the issuance of $200,000 of common stock, payable in two equal installments, with the first installment to be paid upon approval by the Board and the second installment six months after the first installment, to CorProminence, LLC (“CoreIR”) for services rendered pursuant to a Marketing and Consulting Agreement. The first installment of 70,922 shares was issued on February 29, 2024.

Contingent Consideration

Pursuant to the Merger Agreement, each security holder of Metuchen received a right to receive such security holder’s pro rata stock of an aggregate of 1,423,209 shares of Petros Common Stock potentially issuable upon the achievement of certain milestones set forth in the Merger Agreement. The milestones are for the achievement of stock price and market capital